Cost Implications for Novel Therapies and Strategies in the Treatment of NSCLC: Perspectives and Clinical Updates from ASCO 2011

Target Audience:

This activity was developed for physician oncologists and oncology pharmacists.

Learning Objectives:

At the end of this activity, participants will be able to:

• Explain the impact of clinical and health economic data presented at the 2011 ASCO meeting on the care of patients with non–small-cell lung cancer (NSCLC)
• Describe how value-based cancer care is evolving in the changing US healthcare system
• Examine how all stakeholders can implement value-based care in the treatment of NSCLC

Instructions For Credit

There is no fee for this activity. To receive credit, participants must read this CME/CE activity in its entirety and complete the posttest and evaluation. The posttest and evaluation can be completed online at www.mlicme.org/p11054.html. Upon completion of the evaluation and scoring 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the certificate for your records.

For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc., at 609-333-1693 or cgusack@mlicme.org.

Physician Credit Designation

The University of Cincinnati designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Registered Pharmacy Designation

Medical Learning Institute, Inc., is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-11-034-H01-P.

Disclosures

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any offlabel discussions. All identified conflicts of interest are thoroughly vetted by University of Cincinnati and Medical Learning Institute, Inc., for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of University of Cincinnati, Medical Learning Institute, Inc., and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity.

Teresa Haile, RPh, MBA, is a reviewer for MLI and has nothing to disclose faculty disclousures

Ira Klein, MD, has nothing to disclose.

Caroline Helwick, medical writer, has nothing to disclose. She intends to discuss investigational medications for NSCLC.

Disclaimer

The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias toward or promotion for the agent discussed in this program should be inferred.